Ovarian Cancer Clinical Trial
ZK-Epo Given With Carboplatin in Patients With Recurrent Ovarian Cancer
Summary
The purpose of this study is to evaluate whether treatment with a new drug called ZK-Epothilone (ZK-Epo) given with carboplatin in patients with recurrent ovarian cancer, who previously have had a good response with cisplatin or carboplatin, is safe and helps to decrease or stop tumor growth.
Full Description
This study has previously been registered by Berlex, Inc. Berlex, Inc. has been renamed to Bayer HealthCare Pharmaceuticals, Inc.Bayer HealthCare Pharmaceuticals, Inc. is sponsoring this trial.
Eligibility Criteria
Inclusion Criteria:- Must have evidence of ovarian cancer measurable by computed tomography (CT) scan or by CA125 blood levels- No radiation therapy in last 4 weeks- No chemotherapy in last 24 weeks - No immunotherapy in last 4 weeks- Good response after previous treatment with carboplatin or cisplatin and then the ovarian cancer got worse again after at least 6 months- Additional criteria determined at screening visit Exclusion Criteria:- Having had more than one treatment regimen with carboplatin or cisplatin- Prior treatment with other epothilones (e.g. ixabepilone)- Use of any investigational drug in the last 4 weeks- Previous radiation to the whole pelvis- Symptomatic brain tumors requiring radiation to the brain - Active infection- Pregnant or breast feeding- Additional criteria determined at screening visit
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 16 Locations for this study
Tucson Arizona, 85724, United States
Little Rock Arkansas, 72205, United States
Bakersfield California, 93309, United States
La Jolla California, 92093, United States
San Diego California, 92121, United States
Savannah Georgia, 31404, United States
South Bend Indiana, 46617, United States
Baltimore Maryland, 21204, United States
Albuquerque New Mexico, 87131, United States
Winston-Salem North Carolina, 27157, United States
Cleveland Ohio, 44109, United States
Oklahoma City Oklahoma, 73104, United States
Knoxville Tennessee, 37920, United States
Roanoke Virginia, 24014, United States
Calgary Alberta, T2N 4, Canada
Toronto Ontario, M4N 3, Canada
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.